Daktari Diagnostics (Boston, MA) a development-stage point-of-care molecular diagnostics company using microfluidic chromatography and lysate impedance spectrospcopy for a CD4 cell counter device, closed a $2.8M Series A financing. Participants include Partners Innovation Fund, Mass Medical Angels, Norwich Ventures, Launchpad Venture Group, Hub Angels Investment Group and Boston Harbor Angels.